Pimavanserin - ACADIA Pharmaceuticals

Drug Profile

Pimavanserin - ACADIA Pharmaceuticals

Alternative Names: ACP-103; BVF-048; Nuplazid; Pimavanserin tartrate

Latest Information Update: 27 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ACADIA Pharmaceuticals
  • Class Antiparkinsonians; Antipsychotics; Piperidines; Small molecules
  • Mechanism of Action Serotonin 2A receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Psychotic disorders
  • Phase III Schizophrenia
  • Phase II Agitation; Major depressive disorder
  • Discontinued Drug-induced akathisia; Drug-induced dyskinesia; Insomnia

Most Recent Events

  • 20 Sep 2018 The US FDA reaffirms the positive benefit-risk profile of pimavanserin for Psychotic disorders, after reviewing postmarketing data
  • 20 Aug 2018 ACADIA Pharmaceuticals initiates enrolment in a phase III trial for Psychosis disorders in USA (NCT03623321)
  • 11 Jul 2018 ACADIA Pharmaceuticals initiates enrolment in a phase III trial for Psycotic disorders in USA (NCT03575052)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top